Strategic Expansion and Technological Evolution in AI-Powered Cardiothoracic Clinical Research: An Analysis of Qureight’s $20 Million Series B Financing

Nelson Advisors
20 hours ago
10 min read

Executive Summary

The clinical research infrastructure for cardiothoracic therapies is undergoing a structural transition driven by the convergence of deep learning, high-dimensional imaging analytics, and real-world clinical data curation. Cambridge-based health technology enterprise Qureight has closed a $20 Million (£15 Million) Series B funding round led by Molten Ventures, supported by a syndicate of returning institutional investors including Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind and Ascension. This capital injection follows a £6.8 Million ($8.5 million) Series A round in April 2024 and a £1.5 Million seed round in 2022, bringing the company's total capital raised to over $30 Million.

Founded in 2018 by consultant pulmonologist Dr. Muhunthan Thillai and consultant radiologist Dr. Alessandro Ruggiero, Qureight addresses a persistent bottleneck in drug development: the subjective, manual, and unstandardised interpretation of complex thoracic scans. By deploying an end-to-end, regulatory-compliant digital infrastructure and 3D deep learning platform, the company converts unstructured computed tomography (CT) and magnetic resonance imaging (MRI) data into objective, compartment-specific quantitative biomarkers.

The Series B proceeds are primarily dedicated to constructing an in-house specialised AI imaging laboratory housing Qureight’s proprietary 3D chest imaging foundation model. This technological development marks a shift from task-specific narrow AI models toward generalised spatial representations, drastically reducing both the data volume and the development time required to deploy predictive models in new therapeutic indications. Consequently, Qureight is extending its established footprint in fibrotic lung diseases into adjacent, high-unmet-need markets, including asthma, pulmonary hypertension, bronchiectasis, drug-induced lung toxicity and lung cancer.

Platform Architectural Overview

Qureight's core technology operates across four functional layers, integrating clinical ingest directly with advanced spatial algorithms:

Architectural Layer	Structural Components	Operational Functionality
Data Ingestion	Secure pipelines connected to 5 NHS England Trusts and global clinical trial sites.	Ingests real-time, anonymised CT, MRI, and clinical biomarker data directly from hospital systems.
Core AI Engine	Specialized AI Imaging Laboratory and 3D Chest Foundation Model.	Utilizes pre-trained spatial representations to rapidly deploy new disease models with reduced data overhead.
Analytics Layer	Compartment-specific 3D extraction algorithms and synthetic control arm generators.	Quantifies structural disease changes and matches historical trial arms to reduce control group sizes.
CRO Services	Site onboarding engine, protocol standardization and regulatory portal.	Expedites site initiation, automates scan quality control, and delivers validated trial endpoints to biopharma sponsors.

Financial Trajectory and Investor Syndicate Dynamics

Qureight’s financing trajectory illustrates growing institutional confidence in digital Contract Research Organization (CRO) platforms that directly compress drug development timelines. The Series B round was anchored by London-listed Molten Ventures, whose healthtech portfolio targets high-growth European techbio enterprises. The round also saw participation from specialised UK venture capital trusts and quantitative technology investors, demonstrating alignment between clinical validation and algorithmic rigour.

Funding Stage	Date	Capital Raised (USD / GBP)	Lead Investor(s)	Primary Strategic Objectives
Seed Round	February 2022	£1.5M ($1.9M)	Early Stage Syndicate	Initial platform development and pilot clinical trial integrations.
Series A	April 2024	$8.5M / £6.8M	Hargreave Hale AIM VCT	Platform expansion, NHS Trust data integrations, and lung cancer model development.
Series B	July 2026	$20.0M / £15.0M	Molten Ventures	Construction of AI Imaging Lab, deployment of 3D Foundation Model, commercial team scaling, and entry into asthma, PH, and bronchiectasis.

The composition of Qureight’s investor base offers strategic advantages beyond capital provision. Hargreave Hale AIM VCT’s repeated lead and follow-on investments signify strong internal performance metrics and revenue traction across early pharma contracts. Concurrently, the participation of XTX Ventures, the venture arm of quantitative trading firm XTX Markets, underscores the technical novelty and computational validity of Qureight’s 3D deep learning architectures.

The entry of Molten Ventures introduces growth-stage operational expertise. As part of the transaction, Dr. Inga Deakin, Partner at Molten Ventures, and Anna Salim of Hargreave Hale have joined Qureight’s Board of Directors, aligning board governance with aggressive commercial execution. This capital deployment occurs against a favourable macro backdrop: the global lung and heart clinical trials market is projected to expand from its current base to $27.5 Billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. Within the broader clinical research domain, forecasted to exceed $92 Billion globally by 2030, the addressable market for imaging analysis, data curation, and AI-driven precision endpoints in cardiothoracic indications is valued at $6.8 Billion.

Technological Infrastructure: The 3D Chest Foundation Model and AI Laboratory

Historically, clinical trial imaging analysis has functioned as an operational bottleneck for biopharmaceutical sponsors. Traditional Imaging CROs rely heavily on centralised core laboratories where human radiologists manually review 2D cross-sectional slices of CT or MRI scans. This approach suffers from notable structural vulnerabilities, including high inter-observer variability, delayed detection of anatomical progression and the prohibitive cost of training bespoke machine learning models for every distinct pathology.

Qureight’s establishment of an in-house AI imaging laboratory represents a paradigm shift toward self-supervised foundation models in spatial biology and radiology. Rather than training distinct, isolated algorithms for every respiratory condition, the company's 3D chest imaging foundation model is pre-trained on massive, highly curated datasets of volumetric thoracic scans. Because the foundation model inherently learns the deep geometric, structural and physiological representations of human chest anatomy, fine-tuning the model for specific disease endpoints requires significantly fewer labeled training instances. This capability drastically reduces the time-to-market for new predictive diagnostic tools.

Operational Dimension	Legacy Core Lab / Narrow AI Approach	Qureight 3D Foundation Model Platform
Data Requirements	Requires thousands of fully annotated, disease-specific images per model.	Low data thresholds via transfer learning from pre-trained 3D representations.
Development Cycle	12 to 24 months per new disease biomarker module.	Accelerated deployment via the centralized AI Imaging Laboratory.
Spatial Resolution	2D slice sampling; highly prone to slice-selection bias.	Volumetric 3D structural analysis across entire anatomical compartments.
Data Curation & Access	Batch processing; fragmented manual data transfers.	Real-time structured data ingest via strategic NHS Trust digital integration contracts.
Trial Arm Optimisation	Standard randomized control arms requiring large patient cohorts.	Integration of synthetic control arms to minimise control patient requirements.

A core competitive moat underlying Qureight’s platform is its direct data integration infrastructure. The company holds formal research and development contracts with five NHS England Trusts. These partnerships grant Qureight secure, compliant access to real-time, anonymized patient CT scans, clinical biomarkers, and longitudinal outcome endpoints directly from hospital networks. This continuous feed of complex clinical data serves a dual purpose: it continuously refines the foundation model’s underlying predictive capabilities while enabling the NHS to utilise Qureight's platform for clinical research and population health analytics.

Market Expansion: Target Indications and Unmet Need

Qureight established its market presence by addressing Idiopathic Pulmonary Fibrosis (IPF) and related interstitial lung diseases (ILDs). Fibrotic lung diseases represent a natural proving ground for quantitative imaging: progressive scarring alters tissue density and lung architecture in ways that are difficult to quantify visually but are readily detectable via 3D spatial deep learning. With Series B capital, Qureight is executing a structured market expansion into adjacent cardiothoracic therapeutic areas where biopharmaceutical sponsors face severe endpoint measurement challenges.

Therapeutic Target	Disease Pathology & Imaging Challenges	Qureight Quantitative Endpoint Solution
Idiopathic Pulmonary Fibrosis (IPF)(Core Market)	Irreversible alveolar scarring; unpredictable progression rates; high trial failure rates due to noisy functional measurements (FVC).	Volumetric quantification of parenchymal fibrosis changes, enabling early detection of drug response or disease progression.
Asthma (Expansion Target)	Heterogeneous airway inflammation, luminal narrowing, and airway wall thickening; highly variable response to biologic therapies.	Automated 3D bronchial tree segmentation; precise measurement of wall thickness, lumen area, and regional air trapping.
Pulmonary Hypertension (PH)(Expansion Target)	Vascular remodeling, elevated pulmonary arterial pressure, and right ventricular strain; difficult to assess non-invasively.	3D pulmonary vascular tree reconstruction and cardiac compartment analytics, guided by a specialized PH Scientific Advisory Board.
Bronchiectasis Expansion Target)	Permanent widening and distortion of the bronchi, recurrent infections, and mucus plugging; complex structural grading.	Volumetric airway-to-artery ratio calculations and mucus plug quantification across multi-center global trial datasets.
Drug-Induced Lung Toxicity (Expansion Target)	Unintended pulmonary inflammation or fibrosis caused by oncology therapies (e.g., ADCs, checkpoints) and novel biologics.	Sensitive early-warning detection of subtle interstitial density shifts, allowing sponsors to adjust dosing without abandoning candidates.
Lung Cancer (Expansion Target)	Complex tumor microenvironments, heterogeneous therapy responses, and co-existing lung parenchymal disease.	Longitudinal 3D tumor volume tracking integrated with surrounding tissue parenchyma analytics to distinguish treatment response from toxicity.

Qureight's systematic focus on Pulmonary Hypertension (PH) exemplifies its strategy of capturing underserved, high-value clinical niches. Historically, clinical trials in PH have relied on invasive right heart catheterization or imprecise functional tests such as the Six-Minute Walk Distance (6MWD). By establishing a dedicated Scientific Advisory Board composed of global leaders in PH, Qureight is validating non-invasive, imaging-based structural biomarkers that measure pulmonary vascular pruning and right-heart remodeling.

This provides biopharma sponsors with sensitive surrogate endpoints, reducing sample size requirements for Phase II proof-of-concept studies and offering clear quantitative signals early in drug development.

Biopharma Strategic Integration and Commercial Operations

Qureight operates via a commercial model that integrates enterprise software licensing with end-to-end clinical trial execution services. As an AI-native Imaging Contract Research Organisation (CRO), the company handles the complete lifecycle of trial imaging data. When biopharmaceutical sponsors initiate multi-centre global trials, Qureight installs standardised site onboarding protocols, automates real-time scan ingestion and quality control, and applies proprietary 3D algorithms to extract precision endpoints.

The commercial viability of Qureight’s platform is supported by multi-year enterprise contracts with top-tier pharmaceutical and biotechnology companies. For example, Qureight entered a three-year strategic partnership with AstraZeneca to deploy its quantitative imaging analytics across complex respiratory disease pipelines. The collaboration utilises Qureight’s platform to refine patient stratification, measure treatment response in clinical trials, and evaluate novel endpoints.

Similarly, Qureight collaborates with Vicore Pharma to accelerate Phase II trials in Idiopathic Pulmonary Fibrosis (IPF). By deploying proprietary AI biomarkers in real-time, Vicore can observe structural lung stabilisation or reversal, accelerating decision-making at critical trial milestones.

Beyond endpoint extraction, Qureight’s platform addresses fundamental CRO cost drivers through two main mechanisms:

Synthetic Control Arms: By leveraging structured real-world data from NHS England contracts alongside historic trial datasets, Qureight constructs virtual trial cohorts. These synthetic control arms allow biopharma sponsors to reduce the number of physical control-group patients required in Phase II and III studies. This accelerates recruitment timelines, lowers total trial expenditures and resolves the ethical dilemmas associated with placing placebo patients in severe, progressive disease cohorts.
Global Site Onboarding: Imaging protocols in multi-center international trials often face severe delays due to inconsistent scan acquisition parameters across different hospital scanner manufacturers. Qureight’s cloud infrastructure automates scan curation and quality control at the point of ingest, streamlining site onboarding and ensuring dataset uniformity across geographically dispersed clinical sites.

Governance, Competitive Positioning and Risk Metrics

Qureight’s executive leadership combines active NHS clinical expertise with commercial techbio leadership. Co-founder and CEO Dr. Muhunthan Thillai continues to serve as a Consultant Chest Physician at the Royal Papworth Hospital in Cambridge, ensuring that platform development remains aligned with clinical realities. Co-founder and Chief Scientific Officer Dr. Alessandro Ruggiero brings clinical expertise in thoracic radiology.

Board additions following the Series B round, including Dr. Inga Deakin of Molten Ventures and Anna Salim of Hargreave Hale, further strengthen growth-stage governance.

In the competitive landscape, Qureight occupies a distinct position between traditional legacy CROs and niche diagnostic AI developers:

Market Category	Representative Entities	Core Operational Focus	Key Strategic Limitations
Legacy Imaging CROs	Clario, IXICO	Manual central core lab image reader services for global pharma.	High operational overhead, slow processing turnarounds, reliance on 2D manual reads.
Diagnostic Point-Solutions	Brainomix, Perspectum	Hospital acute care diagnostic triage (e.g., stroke, liver mapping).	Focused primarily on acute clinical care rather than biopharma CRO trial execution.
AI-Native Imaging CRO	Qureight	End-to-end 3D deep learning foundation models and precision endpoints for clinical trials.	Requires ongoing regulatory alignment for novel surrogate endpoint approval.

To maintain its market trajectory, Qureight actively manages several operational and regulatory risk factors:

Risk Category	Specific Operational Impact	Risk Mitigation Strategy
Regulatory Validation	Evolving FDA/EMA criteria for accepting AI-generated imaging biomarkers as primary surrogate endpoints.	Validating biomarkers against established clinical endpoints and securing regulatory clearance for exploratory trial arms.
Enterprise Sales Cycles	Prolonged biopharma procurement cycles delaying software platform licensing.	Securing multi-year strategic enterprise contracts (e.g., AstraZeneca) and offering bundled CRO services.
NHS Data Governance	Shifts in public health policies regarding data anonymisation and research access.	Maintaining reciprocal contracts that provide the NHS free platform access for internal clinical research.

Conclusions and Strategic Outlook

Qureight’s $20 Million Series B financing represents a pivotal milestone in the modernisation of cardiothoracic clinical research. By constructing a specialised AI imaging laboratory around a 3D chest foundation model, the company shifts clinical imaging from manual 2D slice interpretation to automated, high-dimensional spatial analytics.

This capability directly addresses long-standing inefficiencies in drug development, enabling biopharmaceutical sponsors to detect disease progression earlier, reduce trial cohort sizes through synthetic control arms, and accelerate time-to-decision.

The company's expansion beyond fibrotic lung diseases into high-unmet-need markets, such as asthma, pulmonary hypertension, bronchiectasis and drug-induced lung toxicity, positions Qureight to capture a expanding share of the $27.5 Billion global lung and heart clinical trials market. Backed by a strong institutional syndicate, strategic NHS data partnerships and validated enterprise relationships with major biopharma leaders like AstraZeneca, Qureight is well positioned to solidify its market leadership as an end-to-end AI imaging CRO, establishing new standards for precision medicine in complex thoracic and cardiovascular care.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics